Analysis of competing risks of causes of death and their variation over different time periods in hodgkin's disease

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5300-5305

  Provencio, Mariano ^a,d   Millán, Isabel ^b   España, Pilar ^a   Sánchez, Antonio C ^a   Sánchez, José J ^b   Cantos, Blanca ^a   Vargas, Juan A ^c   Bellas, Carmen ^d   García, Vanesa ^a   Sabin, Pilar ^a   Bonilla, Felix ^a  

^a Medical Oncology Department   (Spain)

^b Biostatistics   (Spain)

^c Internal Medicine Service   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; KAPLAN MEIER METHOD; MORTALITY; ONSET AGE; RADIATION INJURY; RISK FACTOR; TIME;

ADULT; AGE OF ONSET; CAUSE OF DEATH; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASMS, RADIATION-INDUCED; RISK FACTORS; TIME;

EID: 52649131826     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0927     Document Type: Article

References (31)

1. Provencio M, García-López FJ, Bonilla F, et al. Comparison of the long-term mortality in Hodgkin's disease patients with that of general population. Ann Oncol 1999; 10:1199-205.
2. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term causes-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-9.
3. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
4. ListerTA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
5. De VitaVT, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc Am Assoc Cancer Res1967;8:13.
6. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.
7. Kaplan HS, Rosenberg SA. Extended field radical radiotherapy in advanced Hodgkin's disease. Cancer Res 1966:26:1268-76.
8. Aragón de la Cruz G, Cardenes H, Otero J. et al. Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients. Cancer 1989;63:1799-803.
9. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
10. GooleyTA, LeisenringW, Crowley J, etal. Estimation of failure probabilities in the presence of competing risk: new representations of old estimators. Stat Med 1999;18:695-706.
11. Gray R. A class of k-sample test for comparing the cumulative incidence of competing risks. Ann Stat 1988:16:1141 -54.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc1999;94:496-509.
13. Ng AK, Bernardo P, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101 -8.
14. Foss Abrahamsen A, Egeland T, Hansen S, Langholm R, Holte H, Kvaloy S. Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer 1997;33:2380-3.
15. Provencio M, Espantild;a P, Salas C, Navarro F, Bonilla F. Hodgkin's disease: correlation between causes of death at autopsy and clinical diagnosis. Ann Oncol 2000;11:59-64.
16. Provencio M, España P, Salas C, Sánchez A, Bonilla F. Hodgkin's disease: unsuspected minimal activity in patients that die from causes other than tumoral pro- gresión. Leuk Lymphoma 2001;42:661 -4.
17. Brusamolino E, Baio A, Orlandi E, et al. Long-term in adul patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomicin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487-93.
18. Van Spronsen DJ, Dijkema IM.Vrints LW, et al. Improved survival of Hodgkin's patients in southeast Netherlands since 1972. Eur J Cancer 1997;33: 436-41.
19. Davis S, Dahlberg S, Myers MH, etal. Hodgkin's disease in the United States: a comparison of patients characteristics and survival in the Centralised Cancer Patient Data System and the Surveillance Epidemiology and End Results Program. J Natl Cancer Inst 1987; 78:471-8.
20. Mazza P, Bochia M, Zinzani PL, et al. Hodgkin's disease: summary of twenty years' experience. Haematologica 1992;77:487-93.
21. van Spronsen DJ, Post PN, Crommelin MA, Breed WP, Coebergh JW. Modest decline in late mortality following Hodgkin's disease in the southeastern Netherlands since 1972. Ann Hematol 1998;76:205-9.
22. Van Leeuwen FE, Chorus AM, Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994;12:1063-73.
23. Holm G, Mellstedt H, Bjorkholm M, et al. Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer 1976:37:751 -62.
24. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996;6:225-42.
25. Peng L, Fine JP. Nonparametric quantile inference with competing-risk data. Biometrika 2007;94:735-44.
26. Adams MJ, Lipstitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139-48.
27. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin's disease: disease control and long- term complications. Int J Radiat Oncol Biol Phys1991; 21:447 - 9.
28. Valagussa P, Santoro A, Bonadona G. Thyroid, pulmonary, and cardiac sequellae after treatment for Hodgkin's disease. Ann Oncol 1992;3:S111 -5.
29. Kremer LC, Van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001:19:191 -6.
30. Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001;161:1501-8.
31. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005;23:4574-6.